Mon, Aug 15, 2016
"Except for a couple of CNS (central nervous system) products and one pain product, we are not really missing a major portfolio. We are looking at couple of global products, though they have gone all off LOE (loss of exclusivity) to reintroduce them into India, we are also looking at that aspect of this juncture," Pfizer India Managing Director S Sridhar told analysts.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
